PL2872139T3 - Kompozycja i sposób leczenia depresji i psychozy u ludzi - Google Patents
Kompozycja i sposób leczenia depresji i psychozy u ludziInfo
- Publication number
- PL2872139T3 PL2872139T3 PL13816622T PL13816622T PL2872139T3 PL 2872139 T3 PL2872139 T3 PL 2872139T3 PL 13816622 T PL13816622 T PL 13816622T PL 13816622 T PL13816622 T PL 13816622T PL 2872139 T3 PL2872139 T3 PL 2872139T3
- Authority
- PL
- Poland
- Prior art keywords
- psychosis
- humans
- depression
- treatment
- composition
- Prior art date
Links
- 208000020401 Depressive disease Diseases 0.000 title 1
- 208000028017 Psychotic disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/06—Phenols the aromatic ring being substituted by nitro groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261741114P | 2012-07-12 | 2012-07-12 | |
| US201261741115P | 2012-07-12 | 2012-07-12 | |
| PCT/US2013/049653 WO2014011590A2 (en) | 2012-07-12 | 2013-07-09 | Composition and method for treatment of depression and psychosis in humans |
| EP13816622.8A EP2872139B1 (en) | 2012-07-12 | 2013-07-09 | Composition and method for treatment of depression and psychosis in humans |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2872139T3 true PL2872139T3 (pl) | 2018-06-29 |
Family
ID=49914491
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17181057T PL3263108T3 (pl) | 2012-07-12 | 2013-07-09 | Kompozycja i sposób leczenia depresji i psychozy u ludzi |
| PL13816622T PL2872139T3 (pl) | 2012-07-12 | 2013-07-09 | Kompozycja i sposób leczenia depresji i psychozy u ludzi |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17181057T PL3263108T3 (pl) | 2012-07-12 | 2013-07-09 | Kompozycja i sposób leczenia depresji i psychozy u ludzi |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9737531B2 (pl) |
| EP (2) | EP2872139B1 (pl) |
| JP (2) | JP6416762B2 (pl) |
| CN (2) | CN107875389B (pl) |
| AU (2) | AU2013288827B2 (pl) |
| CA (1) | CA2878565A1 (pl) |
| DK (1) | DK2872139T3 (pl) |
| ES (2) | ES2657895T3 (pl) |
| HU (1) | HUE038023T2 (pl) |
| IL (1) | IL236687A0 (pl) |
| PL (2) | PL3263108T3 (pl) |
| PT (2) | PT2872139T (pl) |
| WO (1) | WO2014011590A2 (pl) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2314362T3 (es) | 2003-01-16 | 2009-03-16 | Acadia Pharmaceuticals Inc. | Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilizados como agentes terapeuticos contra enfermedades neurodegenerativas. |
| US10172810B2 (en) * | 2003-02-24 | 2019-01-08 | Pharmaceutical Productions, Inc. | Transmucosal ketamine delivery composition |
| BRPI0918868B8 (pt) | 2008-09-18 | 2021-05-25 | Naurex Inc | compostos moduladores do receptor de nmda e composições compreendendo os mesmos |
| KR20230098711A (ko) | 2013-01-22 | 2023-07-04 | 비스타젠 쎄라퓨틱스, 인크. | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
| KR20150110586A (ko) | 2013-01-29 | 2015-10-02 | 노렉스, 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| KR20150110787A (ko) | 2013-01-29 | 2015-10-02 | 노렉스, 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| KR102410989B1 (ko) | 2013-01-29 | 2022-06-17 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| TR201908596T4 (tr) | 2013-01-29 | 2019-07-22 | Aptinyx Inc | Spiro-laktam NMDA reseptörü modülatörleri ve bunların kullanımları. |
| SG11201505862TA (en) | 2013-01-29 | 2015-08-28 | Naurex Inc | Spiro-lactam nmda receptor modulators and uses thereof |
| CN106659762A (zh) * | 2014-05-06 | 2017-05-10 | 西北大学 | Nmdar调节化合物的组合 |
| WO2016025721A1 (en) * | 2014-08-14 | 2016-02-18 | Naurex, Inc. | Methods of treating depression using nmda modulators |
| EP3194403B1 (en) | 2014-09-15 | 2019-02-06 | Rugen Holdings (Cayman) Limited | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists |
| WO2016049048A1 (en) * | 2014-09-22 | 2016-03-31 | Rugen Holdings (Cayman) Limited | Treatment of anxiety disorders and autism spectrum disorders |
| JP2018501217A (ja) | 2014-12-02 | 2018-01-18 | 田辺三菱製薬株式会社 | 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン |
| CN107108560B (zh) | 2014-12-23 | 2020-11-10 | 塞里考股份有限公司 | 化合物、组合物及其方法 |
| US10221182B2 (en) | 2015-02-04 | 2019-03-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists |
| US10584127B2 (en) | 2015-06-01 | 2020-03-10 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists |
| HUE055763T2 (hu) | 2015-07-20 | 2021-12-28 | Acadia Pharm Inc | Eljárás N-(4-fluorbenzil)-N-(1-metilpiperidin-4-il)-N'-(4-(2-metil-propil-oxi)fenil-metil)karbamid vagy ennek tartarát-sója és C polimorf formája elõállítására |
| US20170119704A1 (en) * | 2015-10-13 | 2017-05-04 | Ovid Therapeutics Inc. | Treatment of cognitive impairment |
| KR20180102052A (ko) * | 2015-10-16 | 2018-09-14 | 노오쓰웨스턴 유니버시티 | 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용 |
| WO2017117514A1 (en) * | 2015-12-31 | 2017-07-06 | Tung Roger D | Deuterated iti-007 |
| WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
| US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
| WO2017201285A1 (en) | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| KR102128675B1 (ko) | 2016-05-19 | 2020-06-30 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| TWI851224B (zh) * | 2016-05-25 | 2024-08-01 | 日商田邊三菱製藥股份有限公司 | 非思覺失調症病患之負性症狀治療用醫藥組成物 |
| JP2019527235A (ja) | 2016-08-01 | 2019-09-26 | アプティニックス インコーポレイテッド | スピロ−ラクタム及びビス−スピロ−ラクタムｎｍｄａ受容体修飾因子及びその使用 |
| PE20190504A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactam y uso de los mismos |
| PE20190501A1 (es) | 2016-08-01 | 2019-04-10 | Aptinyx Inc | Moduladores nmda espiro-lactam y metodos de uso de los mismos |
| AU2017306136B2 (en) | 2016-08-01 | 2021-10-21 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| AU2017306152A1 (en) | 2016-08-01 | 2019-01-31 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| CA3034895A1 (en) * | 2016-08-26 | 2018-03-01 | Exciva Ug (Haftungsbeschrankt) | Compositions and methods thereof |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| CA3047354A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| US11464768B2 (en) | 2016-12-20 | 2022-10-11 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis |
| CA3047451A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| US20180214395A1 (en) * | 2017-01-31 | 2018-08-02 | Paolo L. Manfredi | Compounds for Treatment or Prevention of Disorders of the Nervous System and Symptoms and Manifestations Thereof, and for Cyto-Protection Against Diseases and Aging of Cells, and Symptoms and Manifestations Thereof |
| US11135211B2 (en) | 2017-04-28 | 2021-10-05 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
| US11478467B2 (en) | 2017-05-04 | 2022-10-25 | Sreenivasarao Vepachedu | Targeted drug rescue with novel compositions, combinations, and methods thereof |
| BR112019022902A2 (pt) * | 2017-05-04 | 2020-05-19 | Exciva GmbH | composição, composição farmacêutica, uso da composição terapeuticamente eficaz, método e uso de uma composição terapeuticamente eficaz em um método de tratamento |
| CN108853510B (zh) * | 2017-05-09 | 2022-05-20 | 浙江大学 | Nmdar抑制剂和t型钙离子通道抑制剂的组合对抑郁症的治疗和药物 |
| CA3064846A1 (en) * | 2017-05-25 | 2018-11-29 | Glytech, Llc | Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders |
| JP7305560B2 (ja) * | 2017-06-12 | 2023-07-10 | グリテック， エルエルシー | Ｎｍｄａアンタゴニスト及びｄ２／５ｈｔ２ａ又は選択的５ｈｔ２ａアンタゴニストによるうつ病の治療 |
| WO2018230713A1 (ja) * | 2017-06-16 | 2018-12-20 | 学校法人同志社 | カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用 |
| CA3067332A1 (en) | 2017-06-16 | 2018-12-20 | The Doshisha | Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof |
| IL271606B2 (en) | 2017-06-21 | 2024-05-01 | Minerva Neurosciences Inc | Gastro-resistant controlled release oral dosage forms |
| CN110799180A (zh) | 2017-06-26 | 2020-02-14 | 罗曼治疗系统股份公司 | 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统 |
| KR102667268B1 (ko) | 2017-07-26 | 2024-05-17 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| WO2019046167A1 (en) | 2017-08-30 | 2019-03-07 | Acadia Pharmaceuticals Inc. | PIMAVANSERIN FORMULATIONS |
| KR102036909B1 (ko) * | 2017-11-28 | 2019-10-25 | 한국과학기술원 | 신규 디스토니아 치료용 약학적 조성물 |
| MX2020008107A (es) | 2018-01-31 | 2020-09-25 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactama y usos de los mismos. |
| CN111936127A (zh) | 2018-02-15 | 2020-11-13 | 国立大学法人千叶大学 | 炎症性疾病或骨病的预防或治疗剂及医药组合物 |
| MX2020009668A (es) * | 2018-03-16 | 2021-01-08 | Intra Cellular Therapies Inc | Métodos novedosos. |
| WO2019237037A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| US12329862B2 (en) | 2018-06-20 | 2025-06-17 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| BR112020026099A2 (pt) | 2018-06-20 | 2021-03-23 | Lts Lohmann Therapie-Systeme Ag | sistema terapêutico transdérmico que contém asenapina |
| CA3108882A1 (en) | 2018-08-21 | 2020-02-27 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| EP3860579A1 (en) | 2018-10-05 | 2021-08-11 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| US12331052B2 (en) | 2018-12-21 | 2025-06-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2020138491A1 (ja) * | 2018-12-27 | 2020-07-02 | 国立大学法人千葉大学 | 神経発達障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 |
| CN109464436A (zh) * | 2019-01-10 | 2019-03-15 | 高智玉 | 西酞普兰或艾司西酞普兰分别和喹硫平联合在制备治疗精神障碍类疾病的复方制剂中的应用 |
| CN114828848A (zh) * | 2019-06-28 | 2022-07-29 | 宾夕法尼亚大学理事会 | 用于治疗阿尔茨海默氏病的鼻内丹曲林施用 |
| JP2022549335A (ja) | 2019-09-25 | 2022-11-24 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
| US11753419B2 (en) | 2019-12-11 | 2023-09-12 | Intra-Cellular Therapies, Inc. | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders |
| US12478592B2 (en) | 2019-12-30 | 2025-11-25 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating neuropsychiatric or neurological conditions |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260324A (en) | 1990-02-06 | 1993-11-09 | G. D. Searle & Company | Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder |
| US5168103A (en) | 1991-01-22 | 1992-12-01 | American Home Products Corporation | [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives |
| DE4118740A1 (de) | 1991-06-05 | 1992-12-10 | Schering Ag | Neue kombinationspraeparate zur behandlung des morbus parkinson |
| GB9208492D0 (en) | 1992-04-16 | 1992-06-03 | Glaxo Spa | Heterocyclic compounds |
| WO1994000124A1 (en) | 1992-06-22 | 1994-01-06 | Eckard Weber | Glycine receptor antagonists and the use thereof |
| DE4222826A1 (de) | 1992-07-09 | 1994-01-13 | Schering Ag | Arzneimittel zur Verhinderung der Toleranzentwicklung während der Behandlung mit Benzodiazepin-Rezeptor-Bindenen Wirkstoffen |
| GB9304500D0 (en) | 1993-03-05 | 1993-04-21 | Glaxo Spa | Heterocyclic compounds |
| GB9319243D0 (en) | 1993-09-17 | 1993-11-03 | Glaxo Spa | Heterocyclic compounds |
| US5801183A (en) | 1995-01-27 | 1998-09-01 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists |
| GB9502695D0 (en) | 1995-02-11 | 1995-03-29 | Glaxo Spa | Pharmaceutical composition |
| GB9507318D0 (en) | 1995-04-07 | 1995-05-31 | Zeneca Ltd | Alpha substituted pyridazino quinoline compounds |
| MY132385A (en) | 1995-08-31 | 2007-10-31 | Novartis Ag | 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives |
| DK0871440T3 (da) | 1995-12-07 | 2006-07-10 | Daniel C Javitt | Behandling af negative og kognitive symptomer på skizofreni med glycinoptagelsesantagonister |
| FR2743366B1 (fr) | 1996-01-10 | 1998-02-06 | Rhone Poulenc Rorer Sa | Derives de 5h,10h-imidazo(1,2-a)indeno(1,2-e)pyrazine-4-one, leur preparation, leurs intermediaires et les medicaments les contenant |
| US5728728A (en) | 1996-04-10 | 1998-03-17 | Kozachuk; Walter E. | Methods of providing neuroprotection |
| US5776935A (en) | 1996-07-25 | 1998-07-07 | Merz & Co. Gmbh & Co. | Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission |
| GB9704499D0 (en) | 1997-03-05 | 1997-04-23 | Glaxo Wellcome Spa | Method of manufacture |
| GB9704498D0 (en) | 1997-03-05 | 1997-04-23 | Glaxo Wellcome Spa | Chemical compound |
| GB9706294D0 (en) | 1997-03-26 | 1997-05-14 | Glaxo Wellcome Spa | Heterocyclic compound |
| WO1998047878A1 (en) | 1997-04-18 | 1998-10-29 | Abbott Laboratories | A process for the preparation of highly pure 6,7-dichloro-5- nitro-2,3-dihydroquinoxaline-2,3-dione |
| AU2030999A (en) | 1998-01-09 | 1999-07-26 | Allelix Neuroscience, Inc. | Glycine transport inhibitors |
| DK1073432T3 (da) * | 1998-04-14 | 2007-12-17 | Gen Hospital Corp | Anvendelse af D serin eller D alanin til behandling af skizofreni |
| EP1186303A3 (en) | 2000-09-06 | 2003-12-10 | Pfizer Products Inc. | Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist |
| ES2314362T3 (es) | 2003-01-16 | 2009-03-16 | Acadia Pharmaceuticals Inc. | Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilizados como agentes terapeuticos contra enfermedades neurodegenerativas. |
| IL154318A (en) * | 2003-02-06 | 2010-05-31 | Sarah Herzog Memorial Hospital | Pharmaceutical compositions for the treatment of movement disorders |
| RS20050851A (sr) * | 2003-05-27 | 2008-04-04 | Forest Laboratories Inc., | Kombinacija antagonista nmda receptora i selektivnog inhibitora ponovnog preuzimanja serotonina za lečenje depresije i drugih poremećaja raspoloženja |
| TW200514775A (en) | 2003-10-22 | 2005-05-01 | Wyeth Corp | Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof |
| WO2005053796A1 (en) | 2003-12-02 | 2005-06-16 | B & B Beheer Nv | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| JP2007517049A (ja) | 2003-12-29 | 2007-06-28 | マクデビット、ジェイソン | 再発性病状を治療するための組成物および方法 |
| EP1734920A2 (en) * | 2004-02-13 | 2006-12-27 | Neuromolecular Inc. | Combination of a nmda receptor antagonist and an mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions |
| KR20070017136A (ko) | 2004-02-13 | 2007-02-08 | 뉴로몰레큘라 파마슈티칼스, 인코포레이티드 | 정신과적 질환의 치료를 위한 ｎｍｄａ 수용체 길항제와항우울제 ｍａｏ 억제제 또는 ｇａｄｐｈ 억제제의 조합물 |
| US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| FR2873294B1 (fr) * | 2004-07-26 | 2008-05-09 | Greenpharma Sa Sa | Association de medicaments |
| US7732615B2 (en) | 2004-09-27 | 2010-06-08 | Acadia Pharmaceuticals Inc. | N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
| JP2008520736A (ja) * | 2004-11-23 | 2008-06-19 | アマダス ファーマシューティカルズ インコーポレイテッド | 持続放出コーティングまたはマトリックスおよびｎｍｄａ受容体アンタゴニストを含む組成物、そのようなｎｍｄａアンタゴニストの被験体への投与方法 |
| WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| EP1858501A1 (en) * | 2005-03-07 | 2007-11-28 | Michael Hermanussen | Nmda receptor antagonists in the medical intervention of metabolic disorders |
| CN101677971A (zh) * | 2007-03-19 | 2010-03-24 | 阿卡蒂亚药品公司 | 5-ht2a反向激动剂和拮抗剂与抗精神病药物的组合 |
| IL188681A0 (en) * | 2008-01-09 | 2008-12-29 | Amino Acid Solutions Inc | Pharmaceutical compositions and methods utilizing a d-amino acid |
| US20100069399A1 (en) * | 2008-09-15 | 2010-03-18 | Auspex Pharmaceutical, Inc. | Arylpiperazine modulators of d2 receptors, 5-ht1a receptors, and/or 5-ht2a receptors |
| BRPI0918868B8 (pt) | 2008-09-18 | 2021-05-25 | Naurex Inc | compostos moduladores do receptor de nmda e composições compreendendo os mesmos |
| WO2010099217A1 (en) * | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| RS53513B1 (sr) | 2009-10-05 | 2015-02-27 | Northwestern University | Glyx-13 za upotrebu u postupku tretiranja refraktornih depresija |
| JP2013519722A (ja) | 2010-02-16 | 2013-05-30 | ファイザー・インク | （ｒ）−４−（（４−（（４−（テトラヒドロフラン−３−イルオキシ）ベンゾ［ｄ］イソオキサゾール−３−イルオキシ）メチル）ピペリジン−１−イル）メチル）テトラヒドロ−２ｈ−ピラン−４−オール、５−ｈｔ４受容体の部分アゴニスト |
| US8735397B2 (en) * | 2010-03-29 | 2014-05-27 | Vanderbilt University | Method for treating schizophrenia and related diseases |
| KR101831616B1 (ko) | 2010-06-15 | 2018-04-04 | 그뤼넨탈 게엠베하 | 통증 치료용 약제학적 병용물 |
| EP2670409B1 (en) | 2011-01-31 | 2018-04-18 | Serotech, LLC | Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder |
| US20130236573A1 (en) * | 2012-03-12 | 2013-09-12 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
-
2013
- 2013-07-07 US US13/936,198 patent/US9737531B2/en active Active
- 2013-07-09 PT PT138166228T patent/PT2872139T/pt unknown
- 2013-07-09 EP EP13816622.8A patent/EP2872139B1/en active Active
- 2013-07-09 CN CN201711339809.7A patent/CN107875389B/zh active Active
- 2013-07-09 AU AU2013288827A patent/AU2013288827B2/en active Active
- 2013-07-09 CA CA2878565A patent/CA2878565A1/en not_active Abandoned
- 2013-07-09 EP EP17181057.5A patent/EP3263108B1/en active Active
- 2013-07-09 HU HUE13816622A patent/HUE038023T2/hu unknown
- 2013-07-09 PL PL17181057T patent/PL3263108T3/pl unknown
- 2013-07-09 DK DK13816622.8T patent/DK2872139T3/en active
- 2013-07-09 ES ES13816622.8T patent/ES2657895T3/es active Active
- 2013-07-09 ES ES17181057T patent/ES2764746T3/es active Active
- 2013-07-09 JP JP2015521708A patent/JP6416762B2/ja active Active
- 2013-07-09 PT PT171810575T patent/PT3263108T/pt unknown
- 2013-07-09 PL PL13816622T patent/PL2872139T3/pl unknown
- 2013-07-09 CN CN201380037202.7A patent/CN104507477B/zh active Active
- 2013-07-09 WO PCT/US2013/049653 patent/WO2014011590A2/en not_active Ceased
-
2015
- 2015-01-12 IL IL236687A patent/IL236687A0/en unknown
- 2015-09-03 US US14/844,021 patent/US9486453B2/en active Active
-
2017
- 2017-07-16 US US15/650,912 patent/US10660887B2/en active Active
-
2018
- 2018-05-15 AU AU2018203371A patent/AU2018203371B2/en active Active
- 2018-10-04 JP JP2018188725A patent/JP2019014740A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN107875389A (zh) | 2018-04-06 |
| US20140018348A1 (en) | 2014-01-16 |
| EP2872139A4 (en) | 2015-08-12 |
| HUE038023T2 (hu) | 2018-09-28 |
| JP2019014740A (ja) | 2019-01-31 |
| US20150374684A1 (en) | 2015-12-31 |
| IL236687A0 (en) | 2015-02-26 |
| EP3263108A1 (en) | 2018-01-03 |
| CN104507477A (zh) | 2015-04-08 |
| WO2014011590A3 (en) | 2014-02-27 |
| EP3263108B1 (en) | 2019-10-02 |
| JP6416762B2 (ja) | 2018-10-31 |
| ES2764746T3 (es) | 2020-06-04 |
| CN107875389B (zh) | 2021-02-02 |
| US9486453B2 (en) | 2016-11-08 |
| US9737531B2 (en) | 2017-08-22 |
| AU2018203371A1 (en) | 2018-06-07 |
| JP2015522075A (ja) | 2015-08-03 |
| DK2872139T3 (en) | 2018-02-05 |
| US20170312275A1 (en) | 2017-11-02 |
| PL3263108T3 (pl) | 2020-06-01 |
| AU2013288827A1 (en) | 2015-02-19 |
| US10660887B2 (en) | 2020-05-26 |
| WO2014011590A2 (en) | 2014-01-16 |
| EP2872139B1 (en) | 2017-11-01 |
| AU2018203371B2 (en) | 2019-11-21 |
| PT3263108T (pt) | 2020-01-15 |
| CA2878565A1 (en) | 2014-01-16 |
| EP2872139A2 (en) | 2015-05-20 |
| PT2872139T (pt) | 2018-02-09 |
| CN104507477B (zh) | 2018-01-19 |
| ES2657895T3 (es) | 2018-03-07 |
| AU2013288827B2 (en) | 2018-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL236687A0 (en) | Composition and method for the treatment of depression and psychosis in humans | |
| ZA201503332B (en) | Water treatment composition and method of using same | |
| EP2890391A4 (en) | METHOD AND COMPOSITION FOR TREATING HYPERGLYCEMIA | |
| IL238416A0 (en) | Preparations and methods for the treatment of diseases caused by protein pathology | |
| IL234792A (en) | Preparation and method of coating | |
| GB201222180D0 (en) | Vehicle and method of control thereof | |
| EP2771030A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES | |
| DK3292875T3 (en) | Compositions and methods for treating diseases | |
| GB2503842B (en) | Composition and method of manufacture | |
| GB201122195D0 (en) | Composition and method | |
| GB201408236D0 (en) | Composition and method | |
| IL234829A0 (en) | Methods and preparations for treating inflammation | |
| AP3773A (en) | Method and composition for sequestration of arsenic | |
| GB201210273D0 (en) | Vehicle and method of control thereof | |
| GB201106433D0 (en) | Composition and method | |
| EP2894964A4 (en) | COMPOSITIONS AND METHOD FOR CONTROLLING FUNGI | |
| ZA201409028B (en) | Cosmetic composition and method for using thereof | |
| ZA201502205B (en) | Ectoparasitic treatment method and composition | |
| GB201222820D0 (en) | Woolscouring method and composition | |
| ZA201409029B (en) | Cosmetic composition and method for using thereof | |
| GB201206859D0 (en) | Method and composition | |
| GB2493595B (en) | Wheelchair and method of construction | |
| ZA201500172B (en) | Plant-disease-control composition and plant-disease-control method | |
| EP2922675A4 (en) | METHOD AND APPARATUS FOR MANUFACTURING COMPOSITE ARTICLES | |
| GB201222736D0 (en) | Composition and process |